Another day, another delay: NIH halts phase 3 study of Lilly's COVID-19 antibody Canaan Partners reels in $800M healthcare and tech fund—again 2nd time’s the charm for Codiak Biosciences and its $83M IPO Ong leaves Biogen to become CEO-partner at Flagship Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B Cyclerion fails sickle cell test, prompting pivot to CNS disease RayzeBio debuts with $45M to target tumors with radiopharmaceuticals Nimbus nets $60M to propel 2 lead programs through the clinic Large genomics study points the way to future cancer clinical trials Featured Story | By Amirah Al Idrus The National Institutes of Health is hitting pause on a phase 3 study testing Eli Lilly and AbCellera’s COVID-19 antibody treatment in hospitalized patients. The reason? “An abundance of caution,” the company says. read more |
| |
|---|
|
| | In our recent 90 Second Insight video, WCG ThreeWire's Molly Hair, Director of Site Engagement and Management, discusses how study staffing shortages due to COVID-19 are affecting clinical research in oncology. Visit wcgclinical.com to see how our Site Support and Augmentation Services can get your oncology trial back on track. |
Top Stories By Amirah Al Idrus No, it’s not a case of déjà vu. Canaan Partners raised $800 million in its 12th fund, equaling the sum it raised in its 11th funds three years ago. “As we start to invest from the new fund, we are expanding in some sectors while our focus remains the same,” the firm wrote in a blog post on Tuesday. read more By Amirah Al Idrus It may have taken 18 months, but Codiak Biosciences is finally on the public markets. The exosome biotech pulled off an $83 million Wall Street debut, falling short of the $100 million it sought in September when it filed to go public for the second time. read more By Nick Paul Taylor Flagship Pioneering has named Tuyen Ong as CEO-partner. The new role sees the ex-Biogen executive join the Flagship senior leadership and serve as CEO of one of its gene therapy startups. read more By Amy Sokolow Potential partners have approached Cambridge-based Dyno Therapeutics since its founding two years ago to get in on the action. Today, Dyno announced its third partnership in the last five months: a $1.8 billion deal with Roche and Spark Therapeutics, a member of the Roche group, to develop central nervous system and liver-directed gene therapies. read more By Nick Paul Taylor Cyclerion Therapeutics has stopped development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial. The setback prompted Cyclerion to switch its focus to IW-6463 and the treatment of diseases of the central nervous system. read more By Amy Sokolow Radiation, one of the most widely used and effective cancer therapies, is traditionally administered through external beams targeted at the site of a tumor—which Ken Song, M.D., CEO of the newly unveiled company RayzeBio, calls “an incredibly effective mode for killing cells.” Song, though, bets that his San Diego-based startup can make it even better with a more targeted approach. read more By Amirah Al Idrus This summer, Nimbus Therapeutics CEO Jeb Kuiper assured us the company wasn’t just a one-hit wonder. Now, it’s reeling in $60 million and signing on two new investors, RA Capital Management and BVF Partners, to prove that out. read more By Angus Liu A large-scale precision medicine study by the ECOG-ACRIN Cancer Research Group and the National Cancer Institute that's focused on tumor genetics has found a high rate of gene abnormalities in tumors that can be targeted with existing drugs. read more | | Experts in our field with 20+ yrs. experience in Viral Vector & Plasmid DNA (R&D, High Quality, GMP) manufacture for pre-clinical to commercial supply. Now part of the Cognate BioServices family, Cobra has rebranded – look around our updated website. Learn more. |
Resources Sponsored By: ICON Clinical Research Ltd The culture of clinical research is evolving from one directed by researchers to one driven by the needs of patients and those who care for them. Sponsored By: The PerkinElmer Signals Screening Team Creating integrated HCS workflows in a single platform increases accuracy; reduces time and helps to identify the most appropriate hits or drug candidates. Learn more about a reliable method for creating a more efficient, faster, 3D image and multi-parametric data analysis workflow. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Cascade Chemistry, API CDMO Struggling with complex chemistry to get APIs for clinical trials? Find out what to look for in an API CDMO partner to gain expertise and speed that lead to success. Sponsored by: EVERSANA An integrated compliance model can be the competitive differentiator to commercialization and move the needle from cost center to value. Learn How. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Formedix Learn how to save time and reduce costs and complexity by streamlining the clinical trial process. Sponsored by: LabVantage Want to leapfrog lengthy LIMS deployments and position your pharmaceutical lab for success? Find out how with LabVantage Solutions. Sponsored by: Thermo Fisher Scientific Learn how to safeguard supply, improve distribution and reduce program costs and risks Sponsored by: Clinical Ink Learn how the right data capture solution can prompt the patient to follow the correct procedures and automatically sort the responses, according to protocol. Sponsored by: Guidehouse While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products. Sponsored by: Blue Matter Consulting Senior executives from 16 biopharma companies share their thoughts on how COVID-19 will change how the industry engages with its customers. A complete Life Science Industry Snapshot in One Report Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Medtech Innovation Week October 19-22 Learn How To Bring A Drug Successfully To Market Oct 21-22, 2020 | Live, Online Drug Development Immersion: Live, Online Course October 21-22, 2020 | 9am - 3:30pm ET Become Fluent In Drug Development With Our Industry Expert October 21-22, 2020 | 9am - 3:30pm ET BioBasics 101: The Biology of Biotech for the Non-Scientist: Live, Online Course November 12-13, 2020 | 9am - 3:30pm ET Drug Development Boot Camp® VIRTUAL 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now | Due to COVID19 provisions – training will be conducted VIRTUALLY | Same excellent total immersion training in new medicine development will be made available to experts who want to make a difference to patients. | 